In iron‑deficiency restless‑legs syndrome, which slow‑release intravenous iron preparation is preferred over iron sucrose and what is its recommended dosing schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Preferred Slow-Release IV Iron Preparation for RLS

For iron-deficiency restless legs syndrome, ferric carboxymaltose is the preferred slow-release intravenous iron preparation over iron sucrose, administered as a single 1000 mg dose. 1

Why Ferric Carboxymaltose Over Iron Sucrose

The 2025 AASM guidelines provide a strong recommendation for IV ferric carboxymaltose in adults with RLS and appropriate iron status (ferritin ≤75 ng/mL or ferritin 75-100 ng/mL), based on moderate certainty evidence from multiple placebo-controlled RCTs. 1

In contrast, iron sucrose is explicitly not recommended for RLS. The guidelines note that high-quality studies of IV iron sucrose failed to show clinically significant benefit over placebo. 1 The critical pharmacologic difference is that iron sucrose is a fast-release, low-dose formulation that lacks the necessary H-ferritin binding and macrophage iron uptake required for iron penetration into the central nervous system—the key therapeutic target in RLS. 1

The slow-release formulations (ferric carboxymaltose, low-molecular weight iron dextran, ferumoxytol, and ferric derisomaltose) allow higher single doses with superior CNS penetration. 1

Recommended Dosing Schedule

Single dose: 1000 mg IV ferric carboxymaltose administered as a one-time infusion. 2, 3, 4

Administration Details:

  • Dilution: Can be given undiluted or diluted in normal saline
  • Infusion time: Typically 15-30 minutes for the full 1000 mg dose
  • Timing of response: Clinical improvement may begin as early as day 8, but full therapeutic effect often requires 12 weeks 2, 5
  • Repeat dosing: May be repeated if iron deficiency recurs or symptoms return

Important Caveats:

Iron parameters for treatment initiation (different from general population): 1

  • Treat if ferritin ≤75 ng/mL OR transferrin saturation <20%
  • Consider treatment even if ferritin is 75-100 ng/mL
  • Target ferritin >100 ng/mL 6

Predictors of response: 7

  • Transferrin saturation ≤35% is the most sensitive predictor of favorable response (more so than ferritin alone)
  • Lower baseline serum iron and %TSAT predict better response, particularly in females
  • Response rates: 64.7% in primary RLS, higher in secondary RLS with iron deficiency anemia (91.3%)

Common pitfall: The initial RCT by Cho et al. (2017) showed only nonsignificant improvement at week 4, reaching significance by week 12. 2 This delayed response means clinicians should not prematurely conclude treatment failure if symptoms don't improve within the first month. Wait at least 12 weeks before assessing efficacy.

Adverse effects: Generally mild, most commonly transient hypophosphatemia. 3 No significant difference in serious adverse events compared to placebo or oral iron. 4, 8

Alternative Slow-Release Formulations

If ferric carboxymaltose is unavailable:

  • Low-molecular weight iron dextran (conditional recommendation, very low certainty evidence) 1
  • Ferumoxytol (conditional recommendation, very low certainty evidence) 1

These receive only conditional recommendations due to limited evidence (single observational studies), but their pharmacologic properties are similar to ferric carboxymaltose. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.